Details for Patent: 8,541,448
✉ Email this page to a colleague
Which drugs does patent 8,541,448 protect, and when does it expire?
Patent 8,541,448 protects IBSRELA and XPHOZAH and is included in two NDAs.
This patent has thirty-seven patent family members in twenty-one countries.
Summary for Patent: 8,541,448
| Title: | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| Abstract: | The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. |
| Inventor(s): | Charmot; Dominique (Campbell, CA), Jacobs; Jeffrey W. (San Mateo, CA), Leadbetter; Michael Robert (San Leandro, CA), Navre; Marc (Belmont, CA), Carreras; Christopher (Belmont, CA), Bell; Noah (Berkeley, CA) |
| Assignee: | Ardelyx, Inc. (Fremont, CA) |
| Application Number: | 13/172,394 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,541,448
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | IBSRELA | tenapanor hydrochloride | TABLET;ORAL | 211801-001 | Sep 12, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-001 | Oct 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| Ardelyx Inc | XPHOZAH | tenapanor hydrochloride | TABLET;ORAL | 213931-002 | Oct 17, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,541,448
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2009334511 | ⤷ Try a Trial | |||
| Brazil | PI0923861 | ⤷ Try a Trial | |||
| Canada | 2748607 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
